377 related articles for article (PubMed ID: 19414940)
1. Spironolactone in chronic hemodialysis patients improves cardiac function.
Taheri S; Mortazavi M; Shahidi S; Pourmoghadas A; Garakyaraghi M; Seirafian S; Eshaghian A; Ghassami M
Saudi J Kidney Dis Transpl; 2009 May; 20(3):392-7. PubMed ID: 19414940
[TBL] [Abstract][Full Text] [Related]
2. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis.
Taheri S; Mortazavi M; Pourmoghadas A; Seyrafian S; Alipour Z; Karimi S
Saudi J Kidney Dis Transpl; 2012 May; 23(3):507-12. PubMed ID: 22569436
[TBL] [Abstract][Full Text] [Related]
3. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.
Hammer F; Malzahn U; Donhauser J; Betz C; Schneider MP; Grupp C; Pollak N; Störk S; Wanner C; Krane V;
Kidney Int; 2019 Apr; 95(4):983-991. PubMed ID: 30712923
[TBL] [Abstract][Full Text] [Related]
5. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
Svensson M; Gustafsson F; Galatius S; Hildebrandt PR; Atar D
J Card Fail; 2004 Aug; 10(4):297-303. PubMed ID: 15309695
[TBL] [Abstract][Full Text] [Related]
6. Spironolactone for heart failure with preserved ejection fraction.
Pitt B; Pfeffer MA; Assmann SF; Boineau R; Anand IS; Claggett B; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Harty B; Heitner JF; Kenwood CT; Lewis EF; O'Meara E; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; Yang S; McKinlay SM;
N Engl J Med; 2014 Apr; 370(15):1383-92. PubMed ID: 24716680
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
8. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
[TBL] [Abstract][Full Text] [Related]
9. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial.
Desai AS; Liu J; Pfeffer MA; Claggett B; Fleg J; Lewis EF; McKinlay S; O'Meara E; Shah SJ; Sweitzer NK; Solomon S; Pitt B
J Card Fail; 2018 May; 24(5):313-320. PubMed ID: 29572190
[TBL] [Abstract][Full Text] [Related]
10. Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients.
Feniman-De-Stefano GM; Zanati-Basan SG; De Stefano LM; Xavier PS; Castro AD; Caramori JC; Barretti P; Franco RJ; Martin LC
Ther Adv Cardiovasc Dis; 2015 Aug; 9(4):158-67. PubMed ID: 26116627
[TBL] [Abstract][Full Text] [Related]
11. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A
Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
[TBL] [Abstract][Full Text] [Related]
13. Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction.
Kurrelmeyer KM; Ashton Y; Xu J; Nagueh SF; Torre-Amione G; Deswal A
J Card Fail; 2014 Aug; 20(8):560-8. PubMed ID: 24905296
[TBL] [Abstract][Full Text] [Related]
14. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
[TBL] [Abstract][Full Text] [Related]
15. Hyperkalemia during spironolactone use in patients with decompensated heart failure.
Lima MV; Ochiai ME; Cardoso JN; Morgado PC; Munhoz RT; Barretto AC
Arq Bras Cardiol; 2008 Sep; 91(3):177-82, 194-9. PubMed ID: 18853060
[TBL] [Abstract][Full Text] [Related]
16. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Pitt B; Zannad F; Remme WJ; Cody R; Castaigne A; Perez A; Palensky J; Wittes J
N Engl J Med; 1999 Sep; 341(10):709-17. PubMed ID: 10471456
[TBL] [Abstract][Full Text] [Related]
17. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, placebo-controlled trial of spironolactone for hypokalemia in continuous ambulatory peritoneal dialysis patients.
Yongsiri S; Thammakumpee J; Prongnamchai S; Tengpraettanakorn P; Chueansuwan R; Tangjaturonrasme S; Dinchuthai P
Ther Apher Dial; 2015 Feb; 19(1):81-6. PubMed ID: 25196890
[TBL] [Abstract][Full Text] [Related]
19. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure.
Vizzardi E; D'Aloia A; Giubbini R; Bordonali T; Bugatti S; Pezzali N; Romeo A; Dei Cas A; Metra M; Dei Cas L
Am J Cardiol; 2010 Nov; 106(9):1292-6. PubMed ID: 21029826
[TBL] [Abstract][Full Text] [Related]
20. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
Gross E; Rothstein M; Dombek S; Juknis HI
Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
